Jade Biosciences, Inc. (JBIO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.03B
Last updated: Nov 17, 2026 at 11:06 AM ET
Jade Biosciences, Inc. (JBIO) Stock Forecast
Analysts expect Jade Biosciences (JBIO) to earn -$2.93 per share in the fiscal year ending Dec 31, 2026. Of 10 analysts, 10 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 10 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 10 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 10
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$2.93
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$2.66
- EPS consensus
- Next report
- Mar 4, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$2.93 | -$2.93 to -$2.93 | 1 |
| Dec 31, 2027 | -$2.66 | -$2.66 to -$2.66 | 1 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.74 | -$0.88 to -$0.55 | 12 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 0 upward and 2 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$2.28.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.93 | -$2.93 | -$2.93 | -$2.93 | -$2.28 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.66 | -$2.66 | -$2.66 | -$2.66 | -$2.28 | N/A |
Frequently Asked Questions About JBIO
What is the JBIO stock forecast?
Consensus analyst estimates put Jade Biosciences's EPS at -$2.93 for the fiscal year ending Dec 31, 2026. The consensus rating from 10 analysts is Buy.
How do analysts rate JBIO stock?
Of 10 analysts covering Jade Biosciences, 0 rate it Strong Buy, 10 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from JBIO next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.93, with estimates from -$2.93 to -$2.93 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.66, with estimates from -$2.66 to -$2.66 from 1 analyst.
How many analysts cover JBIO?
10 analysts rate Jade Biosciences stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
JBIO pages: Overview, Earnings, Forecast, Financials, Competitors